News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Matrixx Initiatives, Inc. Says FDA Declines to Withdraw Warning Letter
March 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Matrixx Initiatives Inc said U.S. health regulators declined to withdraw the warning letter on the company's nasal versions of Zicam cold remedy.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
FDA
BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC
June 24, 2026
·
3 min read
·
Heather McKenzie
Podcast
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more
June 24, 2026
·
1 min read
·
Jef Akst
Manufacturing
With onshoring ‘having a moment,’ Aquestive CEO shares lessons from 20 years of US manufacturing
June 23, 2026
·
4 min read
·
Nick Paul Taylor
Policy
HHS debuts ‘unprecedented’ initiative to ‘restore American leadership’ in clinical trials
June 22, 2026
·
3 min read
·
Heather McKenzie
